
AOD-9604
Modified fragment of growth hormone studied for fat breakdown without affecting blood sugar or growth.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
Pricing coming soon
Contact us for a quote on this batch.
Bacteriostatic water included
About this peptide
AOD-9604 is a short piece of human growth hormone — the tail end (amino acids 177–191) with one extra amino acid added for stability. Researchers isolated this fragment because it appears to carry growth hormone's fat-burning signal without its effects on blood sugar or tissue growth. It was taken through human clinical trials for weight management and is studied today in fat metabolism and cartilage research.
Why researchers reach for AOD-9604
Fat-metabolism research
Studied for stimulating fat breakdown (lipolysis) and blocking new fat formation in fat-cell models.
No blood-sugar effect
Unlike full growth hormone, trials reported no impact on insulin sensitivity or glucose levels.
Human safety data
One of the few peptide fragments with published human safety studies from its clinical-trial programme.
Key features
- 99%+ purity verified by HPLC
- Tyr-modified hGH fragment 177-191
- Lyophilised powder for stability
- 5 mg research vial
- Bacteriostatic water included
- For laboratory research use only
How it works
Growth-hormone tail fragment
Mimics the C-terminal region of hGH that is linked to fat metabolism, without binding the growth-hormone receptor in a way that drives growth.
Lipolysis stimulation
Promotes release of stored fat from adipocytes, partly through beta-3 adrenergic signalling.
Lipogenesis inhibition
Reduces the conversion of dietary energy into new stored fat in animal models.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Reported research range | 250–500 mcg | Per administration in injectable research protocols; human trials used 1 mg/day orally. |
| Frequency | 1× daily | Clinical programmes used daily dosing over 12 weeks. |
| Typical reconstitution | 2 mL bacteriostatic water | Yields 2.5 mg/mL (2500 mcg/mL). |
| Anti-gelling reconstitution | 0.6% sterile acetic acid | Used in place of, or before, bacteriostatic water to keep the peptide fluid and stop gelling. Add slowly down the vial wall and swirl gently — do not shake. |
Tracking this compound? Registered researchers can log active AOD-9604 protocols in their private Research Log.
Timing in research protocols
Once daily; morning fasted timing is protocol convention rather than trial evidence.
- Human clinical trials used once-daily oral dosing for 12 weeks.
- Fasted-morning dosing in research protocols follows growth-hormone fat-metabolism physiology, not a timing trial.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Scientific name
- Tyr-hGH(177-191), anti-obesity drug 9604
- Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- CAS number
- 221231-10-3
- Molecular weight
- ~1815 Da
- Purity
- 99%+ (HPLC)
- Form
- Lyophilised white powder
- Vial size
- 5 mg
- Reconstitution
- 2 ml bacteriostatic water
- Anti-gelling solvent
- 0.6% sterile acetic acid if gelling occurs
- Storage (unopened)
- -20 degrees C, protected from light
- Storage (reconstituted)
- 2-8 degrees C, use within 30 days
Published research
Peer-reviewed literature on AOD-9604. Links open in a new tab.
Research use notice
AOD-9604 is supplied strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical application.
